Apogee Therapeutics, Inc. (APGE)
Develops antibody drugs to treat allergic and inflammatory diseases like eczema and asthma.
$134.17-0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+255.4%
The outlook
APGE is trading near its 52-week high, well above both its 50- and 200-day moving averages. Analyst opinion is mixed, with a consensus "Hold" rating and an average price target sitting roughly 3% below the current price. The stock's technical position remains strong, though analyst coverage suggests caution.
What’s behind the score
Analyst consensusHold — 2.6 avg of 12 analysts
Price trendAbove its 50- & 200-day averages
52-week range100% of the way from its 52-week low to high
Price targetAvg target -3% vs current price
Analyst price target
~12-month · 12 analysts$130.53average target-2.7% vs now
Now $134.17
Low $81.00High $137.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$10.15B
52-wk high
$134.46
52-wk low
$34.34
50-day avg
$108.47
200-day avg
$81.28
Trailing P/E
—